Table 1.
Association of FGFR1 gene copy number, mRNA expression and protein expression with clinicopathological factors
| Total number of patients | FGFR1 amplification | FGFR1 mRNA expression | FGFR1 protein expression | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Normal | Gain/amplification | P‐value | Low | High | P‐value | Low | High | P‐value | ||
| n = 307 | n (%) | n (%) | ||||||||
| Age | ||||||||||
| <50 | 67 | 56 (83.6) | 11 (16.4) | 0.52 | 50 (74.6) | 17 (25.4) | 0.89 | 46 (68.7) | 21 (31.3) | 0.45 |
| ≥50 | 240 | 208 (86.7) | 32 (13.3) | 181 (75.4) | 59 (24.6) | 176 (73.3) | 64 (26.7) | |||
| Menstrual status | ||||||||||
| Premenopause | 79 | 65 (82.3) | 14 (17.7) | 0.28 | 58 (73.4) | 21 (26.6) | 0.62 | 53 (67.1) | 26 (32.9) | 0.24 |
| Postmenopause | 227 | 198 (87.2) | 29 (12.8) | 173 (76.2) | 54 (23.8) | 168 (74.0) | 59 (26.0) | |||
| BMI | ||||||||||
| <23 | 156 | 137 (87.8) | 19 (12.2) | 0.30 | 119 (76.3) | 37 (23.7) | 0.57 | 113 (72.4) | 43 (27.6) | 0.95 |
| ≥23 | 147 | 123 (83.7) | 24 (16.3) | 108 (73.5) | 39 (26.5) | 106 (72.1) | 41 (27.9) | |||
| Nuclear grade | ||||||||||
| 1 | 183 | 165 (90.2) | 18 (9.8) | 0.010* | 138 (75.4) | 45 (24.6) | 0.90 | 129 (70.5) | 54 (29.5) | 0.33 |
| 2, 3 | 123 | 98 (79.7) | 25 (20.3) | 92 (74.8) | 31 (25.2) | 93 (75.6) | 30 (24.4) | |||
| Tumor invasion size | ||||||||||
| ≤20 mm | 170 | 150 (88.2) | 20 (11.8) | 0.21 | 128 (75.3) | 42 (24.7) | 0.98 | 131 (77.1) | 39 (22.9) | 0.039* |
| >20 mm | 137 | 114 (83.2) | 23 (16.8) | 103 (75.2) | 34 (24.8) | 91 (66.4) | 46 (33.6) | |||
| Nodal status | ||||||||||
| − | 201 | 175 (87.1) | 26 (12.9) | 0.46 | 154 (76.6) | 47 (23.4) | 0.45 | 145 (72.1) | 56 (27.9) | 0.93 |
| + | 106 | 89 (84.0) | 17 (16.0) | 77 (72.6) | 29 (27.4) | 77 (72.6) | 29 (27.4) | |||
| Ki67 | ||||||||||
| <15% | 115 | 104 (90.4) | 11 (9.6) | 0.092 | 91 (79.1) | 24 (20.9) | 0.18 | 85 (73.9) | 30 (26.1) | 0.45 |
| ≥15% | 169 | 141 (83.4) | 28 (16.6) | 122 (72.2) | 47 (27.8) | 118 (69.8) | 51 (30.2) | |||
| Histological subtype | ||||||||||
| Pap‐tub ca. | 201 | 175 (87.1) | 26 (12.9) | 154 (76.6) | 47 (23.4) | 146 (72.6) | 55 (27.4) | |||
| Sol‐tub ca. | 28 | 23 (82.1) | 5 (17.9) | 0.44 | 17 (60.7) | 11 (39.3) | 0.12 | 22 (78.6) | 6 (21.4) | 0.12 |
| Scirrhous ca. | 31 | 24 (77.4) | 7 (22.6) | 22 (71.0) | 9 (29.0) | 17 (54.8) | 14 (45.2) | |||
| Other type | 45 | 40 (15.3) | 5 (11.1) | 38 (84.4) | 7 (15.6) | 35 (77.8) | 10 (22.2) | |||
*χ2‐test: P < 0.05. BMI, body mass index; FGFR1, fibroblast growth factor receptor‐1; pap‐tub ca., papillo tubular carcinoma; scirrhous ca., scirrhous carcinoma; sol‐tub ca., solid tubular carcinoma.